ClinicalTrials.Veeva

Menu
K

Klinika Reuma Park Sp. z o.o. sp. k. | Centrum Medyczne Reuma Park

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

JNJ-77242113
ESK-001
Guselkumab
BMS-986165
Zasocitinib
Paracetamol
Icotrokinra
Deucravacitinib
Ibuprofen
Prednisone

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 15 total trials

A Study of Guselkumab Administered Subcutaneously in Bio-naive Participants With Active Psoriatic Arthritis Axial Disease (STAR)

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) axial disease by...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The main purpose of the proposed study is to evaluate the efficacy of efgartigimod PH20 SC in patients with moderate-to-severe Primary Sjögren's Dise...

Enrolling
Primary Sjogrens Disease
Biological: Efgartigimod PH20 SC
Other: Placebo PH20 SC

Psoriatic arthritis (PsA) is a chronic inflammatory disease that affects the joints and skin in people who have psoriasis (PsO).The main aim of the s...

Enrolling
Psoriatic Arthritis
Drug: Active Comparator
Drug: Zasocitinib
Locations recently updated

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling
Systemic Lupus Erythematosus
Drug: Deucravacitinib
Other: Placebo

This is a Phase 2b randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of three active dose regimens of MORF-057 i...

Active, not recruiting
Colitis, Ulcerative
Inflammatory Bowel Diseases
Drug: MORF-057
Drug: Placebo

The goal of this clinical trial is to learn if ESK-001 works to treat moderate to severe plaque psoriasis. The main questions it aims to answer are:*...

Active, not recruiting
Plaque Psoriasis
Drug: Placebo
Drug: Apremilast

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in biologic-experienced participants with active psoriatic a...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Icotrokinra

The purpose of this study is to evaluate the efficacy of icotrokinra compared to placebo in participants with active psoriatic arthritis (PsA) by ass...

Enrolling
Arthritis, Psoriatic
Drug: Placebo
Drug: Active reference comparator

The main purpose of this study is to evaluate the efficacy and safety of LY3871801 in adult participants with active moderately-to-severe rheumatoid...

Enrolling
Rheumatoid Arthritis
Drug: LY3871801
Drug: Placebo

The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) and inadequate re...

Active, not recruiting
Arthritis, Psoriatic
Drug: Placebo
Drug: Guselkumab

The objective of the ESK-001-018 long term extension is to evaluate the safety and efficacy of ESK-001 over time. The scientific questions it aims to...

Enrolling
Psoriasis
Severe Psoriasis
Drug: Open-Label ESK-001
Drug: Blinded ESK-001
New

This is a double-blind, randomized, placebo- and active-controlled study investigating the safety, tolerability, pharmacokinetics (PK), and pharmacod...

Not yet enrolling
Rheumatoid Arthritis
Other: Placebo
Drug: LFD-200

Psoriatic arthritis (PsA) is a type of arthritis that happens when the body's immune system attacks healthy cells and tissues causing joint pain, sti...

Enrolling
Psoriatic Arthritis
Drug: Risankizumab
Drug: Lutikizumab

Trial sponsors

Janssen (J&J Innovative Medicine) logo
A
argenx logo
AbbVie logo
Angelini Pharma logo
Bristol-Myers Squibb (BMS) logo
Lilly logo
Takeda logo
L
M

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems